Sheila Lorente-Pozo

Ms. Sheila Lorente-Pozo


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2018 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
SLSheila Lorente-Pozo
Sheila Lorente-Pozo
ALAnna Parra Llorca
Anna Parra Llorca
BTBegoña Torres
Begoña Torres
Isabel Torres-CuevasIsabel Torres-Cuevas
Isabel Torres-Cuevas
ANAntonio Nuñez-Ramiro
Antonio Nuñez-Ramiro
Maximo VentoMaximo Vento
Maximo Vento
Fetal sex is associated with striking differences during in utero development, fetal-to-neonatal transition, and postnatal morbidity and mortality. Male sex fetuses are apparently protected while in utero resulting in a higher secondary sex rate for males than for females. However, during fetal-to-neonatal transition and thereafter in the newborn period, female exhibits a greater degree of maturation that translates into a better capacity to stabilize, less incidence of prematurity and prematurity-associated morbidities, and better long-term outcomes. The present review addresses the influence of sex during gestation and postnatal adaptation that includes the establishment of an adult-type circulation, the initiation of breathing, endurance when confronted with perinatal hypoxia ischemia, and a gender-related different response to drugs. The intrinsic mechanisms explaining these differences in the perinatal period remain elusive and further experimental and clinical research are therefore stringently needed if an individual oriented therapy is to be developed.

15 May 2019 in Neonatology
Verified
Journal Article
Closed access
PDF file
ANAntonio Nuñez-Ramiro
Antonio Nuñez-Ramiro
IBIsabel Benavente-Fernandez
Isabel Benavente-Fernandez
EVEva Valverde
Eva Valverde
MCMalaika Cordeiro
Malaika Cordeiro
DBDorotea Blanco
Dorotea Blanco
OGon behalf of the Hypotop Study Group
on behalf of the Hypotop Study Group
Background and Objectives: Therapeutic interventions to improve the efficacy of whole-body cooling for hypoxic-ischemic encephalopathy (HIE) are desirable. Topiramate has been effective in reducing brain damage in experimental studies. However, in the clinical setting information is limited to a small number of feasibility trials. We launched a randomized controlled double-blinded topiramate/placebo multicenter trial with the primary objective being to reduce the antiepileptic activity in cooled neonates with HIE and assess if brain damage would be reduced as a consequence. Study Design: Neonates were randomly assigned to topiramate or placebo at the initiation of hypothermia. Topiramate was administered via a nasogastric tube. Brain electric activity was continuously monitored. Topiramate pharmacokinetics, energy-related and Krebs’ cycle intermediates, and lipid peroxidation biomarkers were determined using liquid chromatography-mass spectrometry and MRI for assessing brain damage. Results: Out of 180 eligible patients 110 were randomized, 57 (51.8%) to topiramate and 53 (48.2%) to placebo. No differences in the perinatal or postnatal variables were found. The topiramate group exhibited less seizure burden in the first 24 h of hypothermia (topiramate, n = 14 [25.9%] vs. placebo, n = 22 [42%]); needed less additional medication, and had lower mortality (topiramate, n = 5 [9.2%] vs. placebo, n = 10 [19.2%]); however, these results did not achieve statistical significance. Topiramate achieved a therapeutic range in 37.5 and 75.5% of the patients at 24 and 48 h, respectively. A significant association between serum topiramate levels and seizure activity (p < 0.016) was established. No differences for oxidative stress, energy-related metabolites, or MRI were found. Conclusions: Topiramate reduced seizures in patients achieving therapeutic levels in the first hours after treatment initiation; however, they represented only a part of the study population. Our results warrant further studies with higher loading and maintenance dosing of topiramate.

1 April 2020 in Seminars in Fetal and Neonatal Medicine
Verified
Journal Article
Closed access
SLSheila Lorente-Pozo
Sheila Lorente-Pozo
ALAnna Parra Llorca
Anna Parra Llorca
ILInmaculada Lara-Cantón
Inmaculada Lara-Cantón
ASAlvaro Solaz
Alvaro Solaz
JGJosé LUIS García-Gimenez
José LUIS García-Gimenez
Maximo VentoMaximo Vento
Maximo Vento

1 November 2018 in The Journal of Pediatrics
Verified
Journal Article
Closed access
SLSheila Lorente-Pozo
Sheila Lorente-Pozo
ALAnna Parra Llorca
Anna Parra Llorca
ANAntonio Núñez-Ramiro
Antonio Núñez-Ramiro
MCMaría Cernada
María Cernada
DHDavid Hervás
David Hervás
Maximo VentoMaximo Vento
Maximo Vento

5 November 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
ALAnna Parra Llorca
Anna Parra Llorca
MMMaría Gormaz Moreno
María Gormaz Moreno
SLSheila Lorente-Pozo
Sheila Lorente-Pozo
Maria CernadaMaria Cernada
Maria Cernada
AGAna García-Robles
Ana García-Robles
Maximo VentoMaximo Vento
Maximo Vento
Background: Own mother’s milk (OMM) is the optimal nutrition for preterm infants. However, pasteurized donor human milk (DHM) is a valid alternative. We explored the differences of the transcriptome in exfoliated epithelial intestinal cells (EEIC) of preterm infants receiving full feed with OMM or DHM. Methods: The prospective observational study included preterm infants ≤ 32 weeks’ gestation and/or ≤1500 g birthweight. Total RNA from EEIC were processed for genome-wide expression analysis. Results: Principal component analysis and unsupervised hierarchical clustering analysis revealed two clustered groups corresponding to the OMM and DHM groups that showed differences in the gene expression profile in 1629 transcripts. The OMM group overexpressed lactalbumin alpha gene (LALBA), Cytochrome C oxidase subunit I gene (COX1) and caseins kappa gene (CSN3), beta gene (CSN2) and alpha gene (CSN1S1) and underexpressed Neutrophil Cytosolic Factor 1 gene (NCF1) compared to the DHM group. Conclusions: The transcriptomic analysis of EEIC showed that OMM induced a differential expression of specific genes that may contribute to a more efficient response to a pro-oxidant challenge early in the postnatal period when preterm infants are at a higher risk of oxidative stress. The use of OMM should be strongly promoted in preterm infants.